{"id":680157,"date":"2023-12-07T11:52:01","date_gmt":"2023-12-07T11:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=680157"},"modified":"2023-12-07T11:52:01","modified_gmt":"2023-12-07T11:52:01","slug":"toll-like-receptor-agonists-pipeline-and-clinical-trials-assessment-2023-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-roche-ascendis-pharma-biontech-highlight-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/toll-like-receptor-agonists-pipeline-and-clinical-trials-assessment-2023-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-roche-ascendis-pharma-biontech-highlight-therapeutics_680157.html","title":{"rendered":"Toll Like Receptor agonists Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Roche, Ascendis Pharma, BioNTech, Highlight Therapeutics"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1701881467.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Toll Like Receptor agonists Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Roche, Ascendis Pharma, BioNTech, Highlight Therapeutics\" src=\"https:\/\/www.abnewswire.com\/uploads\/1701881467.jpeg\" alt=\"Toll Like Receptor agonists Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Roche, Ascendis Pharma, BioNTech, Highlight Therapeutics\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">(Las Vegas, Nevada, United States)  As per DelveInsight\u2019s assessment, globally, Toll Like Receptor agonists pipeline constitutes 60+ key companies continuously working towards developing 60+ Toll Like Receptor agonists treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.<\/div>\n<p style=\"text-align: justify;\">The Toll Like Receptor agonists Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/toll-like-receptor-agonist-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Toll Like Receptor agonists Pipeline Insight, 2023<\/a>&#8220;<\/strong> report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Toll Like Receptor agonists Market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key takeaways from the Toll Like Receptor agonists Pipeline Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Companies across the globe are diligently working toward developing novel Toll Like Receptor agonists treatment therapies with a considerable amount of success over the years.&nbsp;<\/li>\n<li>Toll Like Receptor agonists companies working in the treatment market are <strong>Inimmune, Pattern Pharma, Apros Therapeutics, Hoffman-La-Roche, Ascendis Pharma, BioNTech, Highlight Therapeutics, PrEP Biopharm, Seven and Eight Biopharmaceuticals, InDex Pharmaceutical, Primmune Therapeutics, Pattern Pharma, Silverback Therapeutics, Ascendis Pharma, Nektar therapeutics, BioNTech, Eisai Co Ltd, Idera Pharmaceutical, and others<\/strong>, are developing therapies for the Toll Like Receptor agonists treatment&nbsp;<\/li>\n<li>Emerging Toll Like Receptor agonists therapies in the different phases of clinical trials are- <strong>INI-2004, PP-100, APR003, RG 6115, TransCon TLR 7\/8 agonist, BNT411, BO112, PrEP-001, BDB001, Cobitolimod, Research program: TLR7 agonist, P2PAR-100, SBT8230, TransCon TLR 7\/8 agonist, NKTR-262, BNT411, E5564, Tilsotolimod, and others<\/strong> are expected to have a significant impact on the Toll Like Receptor agonists market in the coming years.&nbsp;&nbsp;&nbsp;<\/li>\n<li><strong>In February 2022, Primmune Therapeutics<\/strong> shared preliminary findings concerning <strong>PRTX007<\/strong>, a new oral medication categorized as a small molecule toll-like receptor 7 (TLR7) specific agonist undergoing Phase 1 clinical trials. These results were presented at the Conference on Retroviruses and Opportunistic Infections (CROI). The initial use of PRTX007 in a study involving healthy volunteers demonstrated positive attributes such as a promising safety record, swift absorption leading to the transformation into TLR7 agonist PRX034, and the stimulation of the innate immune system without inducing inflammation.<\/li>\n<li>Pattern&#8217;s primary product, <strong>P2PAR-100,<\/strong> is an immunotherapy treatment designed to trigger innate immune cells, enabling them to eliminate cancerous cells. It achieves this by safely initiating a potent innate and adaptive immune response.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Toll Like Receptor agonists Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Pathogen-associated molecular patterns (PAMPs) include unmethylated double-stranded DNA (CpG), single-stranded RNA (ssRNA), lipoproteins, lipopolysaccharide (LPS), and flagellin. Toll-like receptors (TLRs) are immunological sensors that provide defense. After these bacteria have gotten beyond physical barriers like the mucosa of the intestinal tract or skin, TLRs identify them and trigger immune cell responses.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free Sample PDF Report to know more about Toll Like Receptor agonists Pipeline Therapeutic Assessment-<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/toll-like-receptor-agonist-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/toll-like-receptor-agonist-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Emerging Toll Like Receptor agonists Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>INI-2004:<\/strong> Inimmune<\/li>\n<li><strong>PP-100:<\/strong> Pattern Pharma<\/li>\n<li><strong>APR003:<\/strong> Apros Therapeutics<\/li>\n<li><strong>RG 6115:<\/strong> Hoffman-La-Roche<\/li>\n<li><strong>TransCon TLR 7\/8 agonist:<\/strong> Ascendis Pharma<\/li>\n<li><strong>BNT411:<\/strong> BioNTech<\/li>\n<li><strong>BO112:<\/strong> Highlight Therapeutics<\/li>\n<li><strong>PrEP-001:<\/strong> PrEP Biopharm<\/li>\n<li><strong>BDB001:<\/strong> Seven and Eight Biopharmaceuticals<\/li>\n<li><strong>Cobitolimod:<\/strong> InDex Pharmaceutical<\/li>\n<li><strong>Research program: TLR7 agonist:<\/strong> Primmune Therapeutics<\/li>\n<li><strong>P2PAR-100:<\/strong> Pattern Pharma<\/li>\n<li><strong>SBT8230:<\/strong> Silverback Therapeutics<\/li>\n<li><strong>TransCon TLR 7\/8 agonist:<\/strong> Ascendis Pharma<\/li>\n<li><strong>NKTR-262:<\/strong> Nektar therapeutics<\/li>\n<li><strong>BNT411:<\/strong> BioNTech<\/li>\n<li><strong>E5564:<\/strong> Eisai Co Ltd<\/li>\n<li><strong>Tilsotolimod:<\/strong> Idera Pharmaceutical<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Toll Like Receptor agonists Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">Toll Like Receptor agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical.<\/li>\n<li>Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Toll Like Receptor agonists Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\">Toll Like Receptor agonists Products have been categorized under various Molecule types, such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal Antibody<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy<\/li>\n<li>Product Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Toll Like Receptor agonists Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Toll Like Receptor agonists Assessment by Product Type<\/li>\n<li>Toll Like Receptor agonists By Stage and Product Type<\/li>\n<li>Toll Like Receptor agonists Assessment by Route of Administration<\/li>\n<li>Toll Like Receptor agonists By Stage and Route of Administration<\/li>\n<li>Toll Like Receptor agonists Assessment by Molecule Type<\/li>\n<li>Toll Like Receptor agonists by Stage and Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&#8217;s Toll Like Receptor agonists Report covers around 60+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I)<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Further Toll Like Receptor agonists product details are provided in the report. Download the Toll Like Receptor agonists pipeline report to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/toll-like-receptor-agonist-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">emerging Toll Like Receptor agonists therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key companies in the Toll Like Receptor agonists Therapeutics Market include:<\/strong><\/p>\n<p style=\"text-align: justify;\">Key companies developing therapies for Toll Like Receptor agonists are &#8211; Hoffman-La-Roche, Ascendis Pharma, Nektar therapeutics, BioNTech, Highlight Therapeutics, PrEP Biopharm, TriSalus Life Sciences, Gilead Sciences, InDex Pharmaceuticals, Mologen, Exicure, Birdie Biopharmaceuticals, Seven and Eight Biopharmaceuticals, Primmune Therapeutics, Pattern Pharma, Silverback Therapeutics, Tallac Therapeutics, Inc., ALX Oncology Holdings Inc., Checkmate Pharmaceuticals, AIM ImmunoTech, and others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Toll Like Receptor agonists Pipeline Analysis:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Toll Like Receptor agonists pipeline report provides insights into&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Toll Like Receptor agonists with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Toll Like Receptor agonists Treatment.<\/li>\n<li>Toll Like Receptor agonists key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Toll Like Receptor agonists Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Toll Like Receptor agonists market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report to know more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/toll-like-receptor-agonist-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Toll Like Receptor agonists drugs and therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Toll Like Receptor agonists Pipeline Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>TLRs are among the ideal targets for exploitation in immunotherapy, growing prevalence of inflammatory diseases are some of the important factors that are fueling the Toll Like Receptor agonists Market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Toll Like Receptor agonists Pipeline Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>However, poor understanding in the context of target diseases, lack of clinical data is an impediment to the development of clinical research and other factors are creating obstacles in the Toll Like Receptor agonists Market growth.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of Toll Like Receptor agonists Pipeline Drug Insight&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage: Global<\/strong><\/li>\n<li><strong>Key Toll Like Receptor agonists Companies:<\/strong> Inimmune, Pattern Pharma, Apros Therapeutics, Hoffman-La-Roche, Ascendis Pharma, BioNTech, Highlight Therapeutics, PrEP Biopharm, Seven and Eight Biopharmaceuticals, InDex Pharmaceutical, Primmune Therapeutics, Pattern Pharma, Silverback Therapeutics, Ascendis Pharma, Nektar therapeutics, BioNTech, Eisai Co Ltd, Idera Pharmaceutical, and others<\/li>\n<li><strong>Key Toll Like Receptor agonists Therapies:<\/strong> INI-2004, PP-100, APR003, RG 6115, TransCon TLR 7\/8 agonist, BNT411, BO112, PrEP-001, BDB001, Cobitolimod, Research program: TLR7 agonist, P2PAR-100, SBT8230, TransCon TLR 7\/8 agonist, NKTR-262, BNT411, E5564, Tilsotolimod, and others<\/li>\n<li><strong>Toll Like Receptor agonists Therapeutic Assessment:<\/strong> Toll Like Receptor agonists current marketed and Toll Like Receptor agonists emerging therapies<\/li>\n<li><strong>Toll Like Receptor agonists Market Dynamics: Toll Like Receptor agonists market drivers and Toll Like Receptor agonists market barriers&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report for <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/toll-like-receptor-agonist-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Toll Like Receptor agonists Pipeline Assessment and clinical trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Toll Like Receptor agonists Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Toll Like Receptor agonists Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Toll Like Receptor agonists Overview<\/p>\n<p style=\"text-align: justify;\">4. Toll Like Receptor agonists- Analytical Perspective In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">5. Toll Like Receptor agonists Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">6. Toll Like Receptor agonists Late Stage Products (Phase II\/III)<\/p>\n<p style=\"text-align: justify;\">7. Toll Like Receptor agonists Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">8. Toll Like Receptor agonists Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">9. Toll Like Receptor agonists Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Toll Like Receptor agonists Therapeutics Assessment<\/p>\n<p style=\"text-align: justify;\">11. Toll Like Receptor agonists Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">13. Toll Like Receptor agonists Key Companies<\/p>\n<p style=\"text-align: justify;\">14. Toll Like Receptor agonists Key Products<\/p>\n<p style=\"text-align: justify;\">15. Toll Like Receptor agonists Unmet Needs<\/p>\n<p style=\"text-align: justify;\">16 . Toll Like Receptor agonists Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">17. Toll Like Receptor agonists Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">18. Toll Like Receptor agonists Analyst Views<\/p>\n<p style=\"text-align: justify;\">19. Appendix<\/p>\n<p style=\"text-align: justify;\">20. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75613.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=toll-like-receptor-agonists-pipeline-and-clinical-trials-assessment-2023-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-roche-ascendis-pharma-biontech-highlight-therapeutics\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 8774225362<br \/><strong>Address:<\/strong>27 Drydock Ave  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Boston<br \/><strong>State:<\/strong> MA<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=toll-like-receptor-agonists-pipeline-and-clinical-trials-assessment-2023-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-roche-ascendis-pharma-biontech-highlight-therapeutics\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Las Vegas, Nevada, United States) As per DelveInsight\u2019s assessment, globally, Toll Like Receptor agonists pipeline constitutes 60+ key companies continuously working towards developing 60+ Toll Like Receptor agonists treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/toll-like-receptor-agonists-pipeline-and-clinical-trials-assessment-2023-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-roche-ascendis-pharma-biontech-highlight-therapeutics_680157.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-680157","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/680157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=680157"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/680157\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=680157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=680157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=680157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}